PIN50 the Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis From the Perspective of the Scottish National Health Service (NHS)

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.236
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PGI18 Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C: Submission to the National Institute for Health and Clinical Excellence (NICE)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Safety and Efficacy of Pegylated Interferon Alpha-2a and Ribavirin Combination in Treatment of Egyptian Patients With Chronic Hepatitis C Genotype-4

IOSR Journal of Pharmacy (IOSRPHR)
2014English

The Effect of Pegylated Interferon-Alpha2b and Ribavirin Combination Therapy for Chronic Hepatitis C Infection in Elderly Patients

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2012English

PGI18 Treatment of Chronic Hepatitis C Patients With Peginterferon Alfa-2a or Peginterferon Alfa-2b: A Cost-Effectiveness Analysis for the Portuguese NHS Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Associated With Thyroid Dysfunction

Acta Hepatologica Japonica
Hepatology
2013English

Combination Therapy With Pegylated Interferon Plus Ribavirin in the Treatment of Hepatitis C Virus-Related Thrombocytopenia

Current Therapeutic Research
Pharmacology
2005English

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

The Lancet
Medicine
2010English

Ledipasvir / Sofosbuvir for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Effectiveness Analysis of Treatment With Peginterferon-Alfa-2a Versus Peginterferon-Alfa-2b for Patients With Chronic Hepatitis C Under the Public Payer Perspective in Brazil

Cost Effectiveness and Resource Allocation
Health Policy
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy